




ESTERN
Medical



Oncology Clinical Trials
Leading the way with Insight and Innovation






ESTERN Medical's CRO Life Sciences clinical research division is at the forefront of advancing hematology and oncology clinical research. With a rich portfolio spanning various cancer therapies—such as immuno-oncology, targeted therapies, and emerging modalities like cell and gene therapies—we provide comprehensive solutions tailored to expedite your drug development journey.

Our collaborative approach ensures seamless support across all phases of oncology development, from initial discovery to market access and commercialization. By harnessing innovative technologies and adaptive trial designs, we optimize dosing, accelerate timelines, and maximize cost efficiencies, all while prioritizing patient well-being.

Through biomarker-driven randomization and adaptive trial designs, we target subjects most likely to respond, enriching patient populations and enhancing trial outcomes. Our strategic approach to country selection considers regional standards of care, regulatory nuances, and protocol complexities, ensuring optimal trial execution.

For all your needs in Oncology Clinical Trials, ESTERN Medical CRO Life Sciences Group delivers excellence. We understand that cancer is not a singular ailment but a diverse spectrum of diseases, each characterized by its own intricate scientific and clinical nuances, patient demographics, and therapeutic avenues.

Our Oncology Expertise is dedicated to advancing scientific understanding and supporting patients through meticulous management of pivotal oncology trials. Employing our Trusted Process methodology, we possess the resources, clinical trial proficiency, and developmental acumen necessary to assist our sponsors across all phases of cancer research and development, encompassing Phases I, II, III, and IV.



"We find ourselves amidst an era of promising advancements in experimental cancer therapy. As we transition towards a new paradigm of targeted oncology treatments, it becomes imperative to devise innovative approaches to clinical trial methodology. The challenge lies in effectively integrating mono- and multi-targeted agents with conventional chemotherapy to address the diverse molecular pathways implicated in cancer."

Robert Morgan, JD
Head of Scientific Regulatory Legal Affairs & Quality, ESTERN Medical

Precision in Practice: Navigating Oncology with Advanced Strategies and Specialized Expertise

As of the most recent data, the World Health Organization (WHO) reports that over 19 million people worldwide are diagnosed with cancer annually, a figure that continues to rise. Projections suggest that this number could reach over 20 million new cases yearly by 2025. Despite the increasing prevalence of cancer, treatments for many cancer types of still present significant challenges, often requiring rigorous and multifaceted approaches. However, ongoing advancements in medical research and technology offer hope for improved outcomes and more effective therapies in the future.

Driven by an unwavering commitment to advancement, we have marshaled global, multidisciplinary teams to spearhead a diverse array of oncology research initiatives:

- Our Oncology Practice is helmed by seasoned oncology drug developers endowed with comprehensive insights into clinical oncology trials.
- Each of our project managers and Clinical Monitors boasts substantial exposure to the unique intricacies of cancer research.
- We have overseen Phase I-IV trials spanning a comprehensive spectrum of therapies, endpoints, and cancer indications, from protocol inception through data analysis to the compilation of final study reports.
- Leveraging our proven, proactive recruitment methodologies, we expedite enrollment processes and facilitate participant retention.
- We furnish regulatory consultation services, leveraging our agency-experienced expertise, to navigate the complexities of oncology research across various regulatory landscapes and targeted indications.

In Pursuit of Progress: Connecting with Oncology Investigators

- Our oncology team comprehends the singular challenges associated with patient recruitment in cancer trials. Our seasoned oncology professionals have cultivated robust relationships with key thought leaders, investigators, professional societies, cancer cooperative groups, and patient advocacy organizations. We recognize the invaluable role played by every member of the patient's medical team, as well as the indispensable support offered by the patient's family.
- We facilitate connections between our sponsors and an international network of esteemed clinical oncologists, spanning both, private practice and academic medical institutions.
- Our adept management cadre is strategically dispersed across key regions, possessing indispensable insights into regional regulatory frameworks, medical landscapes, and cultural nuances.
- As pioneers among Contract Research Organizations (CROs) in Latin America and South America, we have forged enduring partnerships with clinical research physicians and medical institutions in pivotal geographic locales, alongside our established presence in U.S. North America.



"Latin America presents a myriad of advantages for conducting oncology clinical trials. We boast oncology opinion leaders trained in the United States or Western Europe who have returned to practice to LATAM. The research medical institutions infrastructure and medical capabilities parallel those of the United States and Europe, with ample patient access, as approximately 80% of the Latin American populace resides in urban centers, facilitating robust trial recruitment."

Dr. Jorge Estrella MD.
President & Chief Medical Officer

Tackling Oncology's Scale: Strategies for Comprehensive Solutions

In both the United States and Latin America, cancer remains a significant public health challenge. In the US, cancer continues to rank as the second leading cause of mortality, with approximately 609,000 deaths and over 1.9 million new diagnoses reported in 2021. Similarly, across Latin America, cancer incidence rates are increasing, with an estimated 1.4 million new cases diagnosed annually. Despite efforts to address the disease, global cancer-related deaths are projected to rise to around 13 million by 2030, highlighting the urgency of the situation. However, there are reasons for optimism as well. Advances in understanding cancer's etiology and behavior are driving research efforts on both continents, fostering collaborations and innovations in prevention, detection, and treatment. By working together to share knowledge and resources, the US and Latin America can make significant strides in combating this global health challenge and improving outcomes for cancer patients worldwide.

Frontiers of Discovery: Exploring Contemporary Oncology Research Trends

The landscape of oncology research is witnessing a rapid expansion, with over 1,000 oncological medicines in development in the United States alone. These therapies, advancing through clinical trials or under review by regulatory bodies like the FDA, mark a pivotal moment in cancer treatment. Sales projections anticipate a robust Compound Annual Growth Rate (CAGR) of approximately 8 percent in the US, driving the market size to an estimated \$150 billion by 2026.

Similarly, in Latin America, there is a burgeoning interest in oncological research, with a growing number of medicines under development and increasing investment in cancer treatment. While specific sales projections for the region may vary, the overall trend reflects significant potential for growth and innovation in cancer therapeutics. Notably, the shift towards personalized medicine is revolutionizing treatment strategies on both continents, aiming to optimize efficacy and minimize adverse effects. With a focus on tailoring treatments to individual patients and tumor types based on genetic profiles, the future of oncology research promises improved patient outcomes and a transformative impact on cancer care across the Americas.

Mastering Oncology Therapeutics: Expertise and Innovation

- Pancreatic
- Myeloma
- Renal
- Melanoma
- Prostate
- Acute & Chronic Leukemia
- Colon
- Brain Tumor
- Cervix
- Hodgkin & Non-Hodgkin Lymphoma
- Lung
- Breast
- Ovarian

Partnering with ESTERN Medical CRO Life Sciences empowers you with access to cutting-edge oncology technologies and unparalleled expertise, propelling your clinical research endeavors toward transformative healthcare outcomes.

Our Partners, Alliances & Sponsors



Our International Presence

- *Boston & Cambridge (USA)
- *Mexico City (Mexico) - *Bogota (Colombia) - *Santiago (Chile) -
- *Buenos Aires (Argentina) - *Sao Paulo (Brazil)

Corporate Address:

ESTERN Medical CRO Life Sciences

955 Massachusetts Ave. No. 203
Cambridge, MA 02139 USA
Tel: +1 (617) 395-0204

To inquire about our CRO Services, please reach out via our company website:
www.esternmedical.com or fill out our company's "Web Contact Us Form", and a member
of our management team will respond to you.



[Follow Us](#)



[Follow Us](#)



[Follow Us](#)